A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN reported. Those medications include semaglutide (Ozempic and Wegovy) and ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Researchers said a single daytime sample of serum 17-hydroxyprogesterone and/or androstenedione is sufficient to monitor ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide, the active ingredient in the drugs.

NEW YORK (Reuters) -Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S. drugs regulator clamps down on mass production of ...

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

For the study, researchers randomly assigned 751 participants with obesity but not Type 2 diabetes to take either tirzepatide, aka Zepbound, or semaglutide, aka Wegovy, weekly, for 72 weeks.

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

None had diabetes, The Associated Press reported. Participants received weekly injections of either Zepbound (tirzepatide) or Wegovy (semaglutide). After 72 weeks, people taking Zepbound lost an ...